Drug Information

Drug General Information
Drug ID
D0CS2C
Former ID
DCL000487
Drug Name
AZD9056
Drug Type
Small molecular drug
Indication Chronic obstructive pulmonary disease [ICD9: 490-492, 494-496; ICD10:J40-J44, J47] Phase 2 [522096], [542771]
Company
AstraZeneca
Structure
Download
2D MOL
Formula
C24H35ClN2O2
InChI
InChI=1S/C24H35ClN2O2/c25-22-5-4-17(3-1-6-26-7-2-8-28)12-21(22)23(29)27-16-24-13-18-9-19(14-24)11-20(10-18)15-24/h4-5,12,18-20,26,28H,1-3,6-11,13-16H2,(H,27,29)
InChIKey
HSQAARMBHJCUOK-UHFFFAOYSA-N
CAS Number
CAS 847254-30-2
PubChem Compound ID
10161381
PubChem Substance ID
15500954, 22559795, 40145537, 80766131, 85156823, 142665573, 198952266, 223366157, 223370279, 223929381, 230083676, 247769184
Target and Pathway
Target(s) P2X purinoceptor 7 Target Info Antagonist [550288]
KEGG Pathway Calcium signaling pathway
Neuroactive ligand-receptor interaction
Reactome The NLRP3 inflammasome
WikiPathways Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
References
Ref 522096ClinicalTrials.gov (NCT00520572) A 6-month Randomised, Double-blind, Open Arm Comparator, Phase IIb, With AZD9056, in Patients With Rheumatoid Arthritis (RA). U.S. National Institutes of Health.
Ref 542771(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7826).
Ref 550288Clinical pipeline report, company report or official report of AstraZeneca (2009).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.